“I’m just not comfortable with with myself” — Inside the grey market peptide boom – London Evening Standard
Unregulated peptide sales surge as patients seek cheaper alternatives to brand-name GLP-1 medications amid shortages and high costs.
Unregulated peptide sales surge as patients seek cheaper alternatives to brand-name GLP-1 medications amid shortages and high costs.
Medical experts challenge stigma around GLP-1 drugs, emphasizing obesity is a chronic disease requiring evidence-based treatment.
GLP-1 drugs like Ozempic show promise treating addiction by targeting brain reward pathways and reducing cravings.
Men are increasingly injecting unregulated peptides for muscle growth despite limited safety data and lack of FDA approval.
Oral GLP-1 drug orforglipron shows 14.7% weight loss in trials, potentially surpassing injectable Ozempic’s effectiveness.
GLP-1 drugs show transformative potential for metabolic health, but accessibility barriers threaten to limit their global impact.
New evidence shows hormone replacement therapy is safe for most women in early menopause, experts say.
India’s peptide therapy market has grown 40% in two years as demand surges for targeted biological treatments.
The popular practice of combining multiple peptides lacks clinical evidence and raises safety concerns despite growing mainstream adoption.
Expert reveals next-generation neurotoxins promise faster results and longer-lasting effects for aesthetic treatments.